OMCL Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of 5.16% compared to Omnicell's net margin of -1.05%. Omnicell's return on equity of 1.04% beat Astrana Health's return on equity of 9.13%.

Omnicell has a consensus price target of $51.00, signalling upside risk potential of 45.67%. On the other hand Astrana Health has an analysts' consensus of $51.9000 which suggests that it could grow by 69.94%. Given that Astrana Health has higher upside potential than Omnicell, analysts believe Astrana Health is more attractive than Omnicell.

Omnicell has a beta of 0.849, which suggesting that the stock is 15.083% less volatile than S&P 500. In comparison Astrana Health has a beta of 1.297, suggesting its more volatile than the S&P 500 by 29.713%.

Omnicell has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omnicell pays -- of its earnings as a dividend. Astrana Health pays out 9.35% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Omnicell quarterly revenues are $306.9M, which are smaller than Astrana Health quarterly revenues of $665.2M. Omnicell's net income of $15.8M is higher than Astrana Health's net income of -$7M. Notably, Omnicell's price-to-earnings ratio is 129.67x while Astrana Health's PE ratio is 34.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell is 1.46x versus 0.72x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of 5.16% compared to Omnicell's net margin of 13.04%. Omnicell's return on equity of 1.04% beat Cryo-Cell International's return on equity of --.

Omnicell has a consensus price target of $51.00, signalling upside risk potential of 45.67%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 35%. Given that Omnicell has higher upside potential than Cryo-Cell International, analysts believe Omnicell is more attractive than Cryo-Cell International.

Omnicell has a beta of 0.849, which suggesting that the stock is 15.083% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.570, suggesting its less volatile than the S&P 500 by 42.967%.

Omnicell has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 7.94% to investors and pays a quarterly dividend of $0.25 per share. Omnicell pays -- of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend.

Omnicell quarterly revenues are $306.9M, which are larger than Cryo-Cell International quarterly revenues of $8.1M. Omnicell's net income of $15.8M is higher than Cryo-Cell International's net income of $1.1M. Notably, Omnicell's price-to-earnings ratio is 129.67x while Cryo-Cell International's PE ratio is 132.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell is 1.46x versus 1.61x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

Phreesia has a net margin of 5.16% compared to Omnicell's net margin of -5.83%. Omnicell's return on equity of 1.04% beat Phreesia's return on equity of -22.95%.

Omnicell has a consensus price target of $51.00, signalling upside risk potential of 45.67%. On the other hand Phreesia has an analysts' consensus of $32.31 which suggests that it could grow by 24.26%. Given that Omnicell has higher upside potential than Phreesia, analysts believe Omnicell is more attractive than Phreesia.

Omnicell has a beta of 0.849, which suggesting that the stock is 15.083% less volatile than S&P 500. In comparison Phreesia has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.564%.

Omnicell has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phreesia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omnicell pays -- of its earnings as a dividend. Phreesia pays out -- of its earnings as a dividend.

Omnicell quarterly revenues are $306.9M, which are larger than Phreesia quarterly revenues of $109.7M. Omnicell's net income of $15.8M is higher than Phreesia's net income of -$6.4M. Notably, Omnicell's price-to-earnings ratio is 129.67x while Phreesia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell is 1.46x versus 3.57x for Phreesia. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of 5.16% compared to Omnicell's net margin of -12.84%. Omnicell's return on equity of 1.04% beat P3 Health Partners's return on equity of -26.35%.

Omnicell has a consensus price target of $51.00, signalling upside risk potential of 45.67%. On the other hand P3 Health Partners has an analysts' consensus of $0.63 which suggests that it could grow by 262.32%. Given that P3 Health Partners has higher upside potential than Omnicell, analysts believe P3 Health Partners is more attractive than Omnicell.

Omnicell has a beta of 0.849, which suggesting that the stock is 15.083% less volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Omnicell has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omnicell pays -- of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

Omnicell quarterly revenues are $306.9M, which are smaller than P3 Health Partners quarterly revenues of $362.1M. Omnicell's net income of $15.8M is higher than P3 Health Partners's net income of -$46.5M. Notably, Omnicell's price-to-earnings ratio is 129.67x while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell is 1.46x versus 0.02x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.